Skip to main content

Table 1 Patient demographics and characteristics at baseline (all-patients-treated set)

From: Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China

  Placebo (n = 158) Rasagiline 1 mg/day (n = 163)
Age, years 61.7 (9.9) 62.7 (8.9)
Gender, male 109 (69%) 103 (63%)
BMI 23.2 (3.3) 23.1 (3.2)
Education (highest level)a
 Elementary/middle school 67 (44%) 68 (43%)
 High school 45 (30%) 41 (26%)
 College/university/graduate 33 (22%) 46 (29%)
 None/other 7 (5%) 3 (2%)
Duration of PD, years 7.1 (4.3) 7.4 (4.8)
Modified Hoehn and Yahr ON 2.0 (0.7) 1.9 (0.7)
Patients with dyskinesia 31 (20%) 49 (30%)
UPDRS-Dyskinesia 0.35 (0.9) 0.49 (1.2)
ON time with troublesome dyskinesia, hours 0.55 (1.8) 0.67 (2.0)
Patients taking concomitant anti-PD medications:b
 Anticholinergics 20 (13%) 21 (13%)
 Amantadine 58 (37%) 50 (31%)
 Dopamine agonistsc 102 (65%) 104 (64%)
 COMT inhibitorsd 31 (20%) 34 (21%)
Data for FAS population (n = 152) (n = 158)
Total daily OFF time, hourse 6.1 (2.7) 6.1 (2.6)
Total daily ON time, hourse 9.3 (2.5) 9.4 (2.4)
UPDRS-ADL OFF 16.5 (7.5) 15.6 (7.2)
UPDRS-ADL ON 7.3 (5.1) 6.8 (4.6)
UPDRS-Motor ON 25.6 (10.5) 23.8 (10.5)
CGI-S 4.1 (0.8) 3.9 (0.8)
Total daily levodopa dose, mg 550 (224) 501 (222)
Total daily levodopa dose at end of Week 4, mgf 549 (225) 495 (219)
  1. aFAS population (n = 152 for placebo group, n = 158 for rasagiline group)
  2. bmedication that was continued after the first study treatment dose
  3. cbromocriptine, piribedil, pramipexole, pramipexole dihydrochloride; ropinirole hydrochloride
  4. dentacapone
  5. en = 150 for placebo group
  6. fFAS, OC (n = 151 for placebo group, n = 157 for rasagiline group)